Skip to content
buyWeak

Philip G Brace bought $124k of INSG

Executive Chairman at INSEEGO CORP.. 10,000 shares at an average of $12.40, traded Nov 15, 2024, filed Nov 18, 2024.

Conviction score
33
Value
$124k
10,000 shares
Holdings after
177,763
+6% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Chair
    +20
  • Trade size
    $124k at market
    +10
  • Relative to holdings
    Holdings up 6%
    +3
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -12.9%, 3m +0.5%, 6m -30.0%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

INSGOct 9, 2026 · close 4.58
Since filing Nov 18, 2024: -64.3%SPY +35.4% · excess -99.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001683168-24-008202, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 15, 2024POpen-market purchase
Common Stock
+10,000$12.40$124k177,763Nov 18, 2024

Related signals

Other insiders at INSEEGO CORP. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
38Weak
INSGbuy
INSEEGO CORP.
Juho Sarvikas
CEO
$98k
10,000 shares
+8%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.